| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.1 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.1 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.053 | 0.1 |